Navigation Links
BELLUS Health reports results for the fourth quarter of 2008
Date:2/26/2009

ry 25, 2009.

Results of operations

Net sales amounted to $157,000 for the current quarter ($310,000 for the year) and represent the initial sales of VIVIMIND(TM) (also known as tramiprosate and homotaurine), the Company's first natural health brand launched in Canada and globally on the Internet on September 2, 2008. VIVIMIND(TM), to protect memory function, is based on homotaurine, a naturally occurring ingredient found in certain seaweed. Targeted at healthy baby boomers, this patented natural health brand is expected to address a largely underserved self-care market by providing a scientific, evidence-based health solution. VIVIMIND(TM) is the direct result of over 15 years of significant scientific research, including clinical testing in over 2,000 individuals. Post-hoc analysis of the North American Phase III clinical trial of homotaurine (VIVIMIND(TM)) involving 1,052 Alzheimer's disease (AD) patients showed a positive impact on cognitive function and that, anatomically, it helped to reduce the volume loss of the hippocampus, an important area of the brain responsible for memory. VIVIMIND(TM) is commercialized by OVOS Natural Health Inc., a wholly owned subsidiary of BELLUS Health. BELLUS Health's strategy includes revenue generation in the short- to medium-term through the sale of natural health products and in the medium- to long-term through development of a pipeline of pharmaceutical products.

Revenue from collaboration agreement amounted to nil for the current quarter ($205,000 for the year), compared to $206,000 for the same period the previous year ($1,119,000 for the year). This revenue was earned under the agreement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product candidate for the treatment of Amyloid A (AA) amyloidosis. During the first quarter of 2008, the Company announced its decision to continue the drug development program for eprodisate (KIACTA(TM))
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations on ... pulmonary embolism are published today in new ESC ... by Professor Stavros V. Konstantinides (Germany/Greece) and Professor ... on the diagnosis and management of acute pulmonary ... Journal (1) and on the ESC Website. , ...
(Date:8/29/2014)... Indosoft, Inc. , a leading provider ... of its most advanced contact center product, Q-Suite 5.7.7. ... as well as updates to existing aspects of its ... on the presentation side has received an update with ... builder. This WYSIWYG editor allows admins to easily ...
(Date:8/29/2014)... Colorado (PRWEB) August 29, 2014 According to ... a popular way to lose weight quickly, safely and naturally. ... it claims to be amazingly fast, too. , Daily ... new method will not only teach patients how to eliminate ... maintain the desired results when it comes to body modeling. ...
(Date:8/29/2014)... The new review that can be read on ... system that will permanently eliminate the symptoms of this disease. ... achieve a cure in as fast as 30 to 60 ... about one week. , The Tinnitus Miracle review indicates ... mild hearing loss, pain in the ear and dizziness. Read ...
(Date:8/29/2014)... Denver, CO (PRWEB) August 29, 2014 ... panic attack is the feeling of intense stress and ... entire life of the sufferer, causing insecurity and affecting ... numerous factors and there are many symptoms that patients ... stress are among these symptoms. Overcoming panic attacks is ...
Breaking Medicine News(10 mins):Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Indosoft Releases Q-Suite 5.7.7 2Health News:Flat Belly Forever Review Exposes the Way to Eliminate Body Fat Easily 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2
... survey conducted by the Scottish executives large numbers of Scots ... The researchers feel that memory loss is associated with long-term ... situations, becoming a target for rapists. ,This survey ... percentage was losing their memories as a result of alcohol. ...
... openness are the tenets that define ideal relationships, has anyone ... past sexual relationships? The need for such revelations, assumes ... ,Value system is one thing, but the dictates of law ... of toeing with legal procedures. So where is the ...
... which began in Jalgaon, on March 29, following fresh ... authorities along with the Maharashtra// Animal Husbandry Department officials ... from six tehsils in Jalgaon district. ,The ... 82 teams. According to Dr B K Wankhade, Regional ...
... Delhi High Court Monday issued notice to the National ... a public interest litigation seeking legal// sanction to homosexuality., ... of section 377 of the Indian Penal Code (IPC) ... offence and punishable with imprisonment up to 10 years., ...
... that the culling operations in Jalgoan where a fresh outbreak ... B K Wankhade, Regional District Commissioner, Animal Husbandry said that ... outbreak was reported ,500 health workers in 82 ... owners had been compensated to the tune of Rs 1 ...
... that immune system gets boosted in people who are prone ... risk of brain cancer. // ,"It appears that ... Scheurer, the study's lead author. "They seem to produce enough ... and working to prevent cancer from beginning to develop.", reports ...
Cached Medicine News:
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 2011 Cynosure, Inc. (Nasdaq: CYNO ), ... invasive and non-invasive aesthetic applications, today announced that two ... cellulite reduction have received key international regulatory clearances. ... License authorizing the sale in Canada of the company,s ...
... SANTA CLARA, Calif., March 15, 2011 NewCardio, Inc. (OTC Bulletin ... today that the Company expects to file its Form 10-K for ... management will conduct a conference call to provide a corporate update ... Corporate Update Conference Call When : 1:30 p.m. ...
Cached Medicine Technology:Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 2Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 3NewCardio to Conduct Corporate Update Conference Call on March 29, 2011 2
Beta-2 Microglobulin EIA Lipid / Protein Quantification 025-BC-1061...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Human Growth Hormone EIA Endocrine Function 025-BC-1033...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
Medicine Products: